Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
March 13, 2024 16:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024 16:05 ET
|
Caribou Biosciences, Inc.
-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for...
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant
March 11, 2024 08:15 ET
|
Napigen, Inc.
The USPTO issued a patent to NAPIGEN for the use of CRISPR technologies to edit organellar genomes. Separately, USDA awarded NAPIGEN an SBIR phase 1 grant.
CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time
March 08, 2024 14:39 ET
|
Pairwise
Durham, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- The panel “The First CRISPR Foods Have Arrived” at this year’s SXSW Conference included leading agricultural scientists, researchers, and innovation...
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024 16:30 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
Asia-Pacific Gene Editing Technology Research Report 2024
February 29, 2024 10:03 ET
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Gene Editing Technologies Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.The...
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 15, 2024 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Global CRISPR Genomic Cure Market Set to Soar with 29.21% CAGR till 2028, Driven by Tech Advancements and Therapeutic Expansion
February 08, 2024 10:00 ET
|
Research and Markets
Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "Crispr Genomic Cure Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ...
Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors
January 30, 2024 08:00 ET
|
Tome Biosciences
Tome Biosciences appoints Daniel Curran, MD, to its Board of Directors.